Clinical Trials

376 enrolled

Breast Neoplasms

NCT07173751 2026-05-22

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

558 enrolled

Breast Neoplasms

NCT06006273 2026-05-20

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

Phase 1 Recruiting

48 enrolled

Other solid neoplasm

Refractory Solid Tumors

NCT05374512 2026-05-15

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

644 enrolled 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT03237780 2026-05-13

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

72 enrolled

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT04579224 2026-05-13

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

184 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05347134 2026-05-08

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

254 enrolled

Triple Negative Breast Neoplasms

NCT06081959 2026-05-08

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

376 enrolled

Breast Neoplasms

NCT06279364 2026-05-08

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

524 enrolled

Triple Negative Breast Neoplasms

NCT05104866 2026-05-05

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

732 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT05570253 2026-04-27

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

55 enrolled

Phase 1/2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07494448 2026-04-23

JAZMINE

24 enrolled

Breast Neoplasms

NCT06382142 2026-04-20

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)

418 enrolled

Triple Negative Breast Neoplasms

NCT06343948 2026-04-17

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)

383 enrolled

HR+HER2- Breast Cancer

NCT07007559 2026-04-13

ASPEN-09-03

120 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07520760 2026-04-09

MBC-EA

52 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT03361436 2026-04-08

Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery

15 enrolled

Liposarcoma

NCT05458674 2026-04-03

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

30 enrolled

Breast Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

792 enrolled

Breast Neoplasms

NCT07203729 2026-03-16

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

184 enrolled

Breast Neoplasms

NCT06875128 2026-03-13

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

90 enrolled

Breast Neoplasms

NCT05810870 2026-03-10

SABINA

14 enrolled

Breast Neoplasms

NCT07441512 2026-03-02

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation

26 enrolled

Triple Negative Breast Neoplasms

NCT06449222 2026-02-25

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

83 enrolled

Phase 3 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07406542 2026-02-12

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

400 enrolled

Breast Neoplasms, Recurrence

NCT06435429 2026-02-10

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

550 enrolled

Metastatic HER2-positive Breast Cancer

NCT04639986 2026-02-09

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

331 enrolled

Breast Neoplasms

NCT06519370 2026-01-22

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

350 enrolled

Triple Negative Breast Neoplasms

NCT06957886 2026-01-21

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

566 enrolled

HER2-low Breast Cancer

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT07333937 2026-01-12

NETHER

35 enrolled

Brest Cancer

NCT03331250 2025-12-23

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

13 enrolled 9 charts

Hemangiosarcoma, Hemangioendothelioma, Epithelioid

NCT04711824 2025-12-23

SOLARA

Phase 1/2 Recruiting

41 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03202316 2025-12-16

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

37 enrolled

Inflammatory Breast Neoplasms

NCT07088263 2025-12-11

Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer

192 enrolled

Breast Neoplasms

NCT03526679 2025-12-05

LEADER

Phase 1/2 Completed

30 enrolled 9 charts

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT07255612 2025-12-01

Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)

29 enrolled

Breast Neoplasms

NCT02623972 2025-11-25

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

22 enrolled 12 charts

Inflammatory Breast Neoplasms

NCT05530057 2025-11-20

ESPERO

180 enrolled

Advanced Breast Cancer

NCT04986579 2025-11-19

Scalp Cooling in MBC

120 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT06328738 2025-11-19

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

275 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT01676818 2025-11-06

Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer

Phase 2 Completed

32 enrolled 17 charts

Gynecologic

Uterine Cervical Neoplasms

NCT06957431 2025-10-24

Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma

Phase 1 Recruiting

18 enrolled

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

557 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT07205185 2025-10-03

A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.

46 enrolled

NCT03264547 2025-09-29

EMERALD

Phase 3 Completed

446 enrolled

Breast Neoplasms

NCT06942234 2025-09-17

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

Phase 1/2 Recruiting

180 enrolled

Inoperable Locally Advanced HER2-Negative Breast Cancer

NCT06079983 2025-09-12

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

400 enrolled

Breast Neoplasms

NCT02514681 2025-09-10

PRECIOUS

Phase 3 Completed

226 enrolled